Geert R. Pecha Kucha

Top-down therapy for IBD: rationale and requisite evidence

Vitamin D deficiency in Crohn's disease and healthy controls: A prospective case–control study in the Netherlands

Recent developments in the treatment of inflammatory bowel disease

212 Serum CRP Is a Better Early Marker for Response to Infliximab Induction Therapy Than Fecal Calprotectin in Patients With Moderate to Severe Ulcerative Colitis

Sa1207 Leukocyte Scintigraphy As a Tool to Measure Inflammatory Load in Ulcerative Colitis

Su1209 Reduced Length of Hospitalisation and Treatment Costs With Infliximab Versus Ciclosporin in Patients With Severe Ulcerative Colitis

867 Anti-MAdCAM Monoclonal Antibody PF-00547659 Does Not Affect Immune Surveillance in the Central Nervous System of Crohn's Disease Patients Who Are Anti-TNF Inadequate Responders:

Su1344 Failure of Infliximab Treatment in Crohn's Disease Is Associated With the Presence of Fibrosis

Tu1151 Re-Introduction of Infliximab After Consecutive Failure of Infliximab and Adalimumab Is Beneficial in Refractory Crohn's Disease

Su1123 Top-Down Versus Step-Up Treatment in Newly Diagnosed Crohn's Disease: No Difference in Long-Term Outcome

786 The Pharmacokinetics of Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

157 Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease

Sa1198 Agreement Among Experts in the Endoscopic Evaluation of Postoperative Recurrence in Crohn's Disease Using the Rutgeerts Score

Su1343 Fibrosis Does Not Increase With Disease Duration in Ulcerative Colitis

Su1371 High Infliximab Trough Levels Are Associated With Impaired Quality of Life in IBD Patients in Clinical and Biochemical Remission on Maintenance IFX Therapy

Vedolizumab for the treatment of ulcerative colitis

Analysing the farm level economic impact of GM corn in the Philippines

Review: Clinical Variability and Genetic Heterogeneity in Multiple Epiphyseal Dysplasia

Institutional and Strategic Barriers to Public—Private Partnership: An Analysis of Dutch Cases